Results of Operations for the First Half of the Fiscal Year Ending March 31, 2016 (April 1, 2015 to September 30, 2015)


November 18, 2015



(Tokyo Stock Exchange, First Section / Stock code: 3341)


I. Results for 1H FY3/16

Copyright 2015 Nihon Chouzai Co., Ltd. All rights reserved.



1H Consolidated Operating Income

Record high profits!



Page 2

P

NIHON CHOUZAI

Consolidated Statement of Income

Page 3 NIHON CHOUZAI

Successfully reached the first-half target for the first fiscal year of the new medium-term management plan!

-Strong YoY growth in sales and earnings-

(Millions of yen)

	1H FY3/14	1H FY3/15	1H FY3/16	Difference	YoY growth rate	1H FY3/16 Initial forecast	Achievement ratio
Net sales	80,136	87,418	100,269	12,851	14.7%	97,980	102.3%
Cost of sales	67,575	72,571	82,369	9,797	13.5%	80,698	102.1%
Gross profit	12,560	14,846	17,900	3,053	20.6%	17,282	103.6%
SG&A expenses	10,222	12,223	13,685	1,461	12.0%	14,355	95.3%
Operating income	2,338	2,623	4,214	1,591	60.7%	2,926	144.0%
% to sales	2.9%	3.0%	4.2%	-	-	3.0%	-
Ordinary income	2,049	2,318	3,936	1,617	69.8%	2,553	154.1%
Net income	950	1,157	2,471	1,313	113.4%	1,195	206.7%

*Non-deductible consumption taxes are included in SG&A expenses.



Upwardly revised the consolidated forecast for FY3/16

(Millions of yen)

	April 30, 2015	October 29, 2015		(Reference)
	Initial forecast	Revised forecast	YoY change	FY3/15 results
Net sales	207,523	220,455	21.2%	181,844
Operating income	8,200	10,742	61.6%	6,647
% to sales	4.0%	4.9%	-	3.7%
Ordinary income	7,434	9,491	58.1%	6,003
Net income	3,583	5,611	102.0%	2,778

Sales increased in all business segments!

-Rapid growth of the medical professional staffing and placement business continued with first half sales up almost 50% from one year earlier-

(Millions of yen)

	1H FY3/15	1H FY3/16	Comp.	Difference	YoY growth rate
Dispensing pharmacy business	75,967	87,204	87.0%	11,237	14.8%
Non-prescription drugs	916	912	0.9%	-4	-0.5%
Pharmaceutical manufacturing and sales business	8,985	9,398	9.4%	412	4.6%
Medical professional staffing and placement business	2,465	3,666	3.7%	1,200	48.7%

SG&A expense growth was far below the increase in gross profit.

-Pharmaceutical manufacturing and sales business R&D expenses are expected to increase from the third quarter onwards-

		1H FY3/15	1H FY3/16	Comp.	Difference	YoY growth rate
SG	i&A expenses	12,223	13,685	13.6%	1,461	12.0%
	Salaries and allowances	1,635	1,851	1.8%	216	13.2%
	Rent	1,088	1,025	1.0%	-63	-5.8%
	Consumption taxes	4,686	5,464	5.5%	778	16.6%
	R&D expenses	791	890	0.9%	98	12.5%

(Millions of yen)

* "Comp." percentages are relative to sales.

Page 7

🕑 NIHON CHOUZAI

			(Millions of yer	ו)	
	End of Mar. 2015	End of Sep. 2015	Difference	Major componen	ts
Current assets	60,096	69,882	9,785	Current assets	
Non-current assets	70,044	70,948	904	 Cash and deposits Merchandise and finished good 	+6,402 ods
Property, plant and equipment	48,819	49,934	1,114	Non-current assets	+2,005
Intangible assets	10,376	10,106	-269	8	+3,348 -3,859
Investments and other assets	10,848	10,907	59	<u>Current liabilities</u>	
Total assets	130,141	140,831	10,689	Short-term loans payable	+5,455 -3,890 +7,000
Current liabilities	53,474	62,314	8,839		17,000
Non-current liabilities	59,031	58,672	-358	 <u>Non-current liabilities</u> Long-term loans payable 	+6,855
Total liabilities	112,505	120,986	8,480		-7,000
Total net assets	17,635	19,844	2,209	• <u>Net assets</u>	2 225
Shareholders' equity	17,635	19,844	2,209	• Retained earnings +	-2,225
Equity ratio	13.6%	14.1%	-	-	

Consolidated Statement of Cash Flows




		(Millions of yen)
	1H FY3/15	1H FY3/16	
Net cash provided by operating activities	1,502	7,435	<u>Ne</u> ●
Net cash used in investing activities	-3,394	-3,329	• C a • C • I
Net cash provided by financing activities	3,575	2,403	a • li
Net increase in cash and cash equivalents	1,682	6,509	• P e
Cash and cash equivalents at beginning of period	15,027	13,844	<u>Ne</u> • N s • P
Cash and cash equivalents at end of period	16,710	20,354	la • R Ia

Major components

	Net cash provided by operating activ	
Γ	 Income before income taxes and n 	on-
	controlling interests	3 <i>,</i> 845
	 Depreciation 	2,124
	 Decrease (increase) in notes and 	
	accounts payable-trade	-920
1	• Decrease (increase) in inventories	-2,917
I	• Increase (decrease) in notes and	
I	accounts payable-trade	+5,318
I	Income taxes paid	-1,317
I	·	
L	-Net cash used in investing activities	
	• Purchase of property, plant and	
	equipment	-2,961
	Net cash provided by financing activ	<u>ities</u>
	• Net increase (decrease) in	
	short-term loans payable	-3,890
	 Proceeds from long-term 	
	loans payable	9,800
	Repayments of long-term	
	loans payable	-2,825
	loans payable • Repayments of long-term	

Dispensing Pharmacy Business: Segment Sales / Operating Income

NIHON CHOUZAI



P

Page 9

Page 10 NIHON CHOUZAI

Nihon Chouzai Group: Store Sales by Year of Opening (Milling)					(Millions of yen)
	No. of pharmacies at end of Sep. 2015	1H FY3/15	1H FY3/16	Difference	YoY growth rate
Existing pharmacies (until Mar. 2014)	474	73,628	81,777	8,148	11.1%
Opened FY3/15 (Apr. 2014 to Mar. 2015)	29	612	3,551	2,939	480.2%
Opened FY3/16 (Apr. 2015 to Sep. 2015)	18	-	769	769	-
Others	-	697	43	-654	-93.8%
Total	521	74,939	86,141	11,202	14.9%

• Sales are only for prescriptions (do not include over-the-counter drugs, etc.) and are recorded when prescriptions are filled (no adjustment for returned prescriptions).

- Sales of pharmacies that were closed are included in the others category.
- The number of pharmacies does not include one location specializing in the sales of general merchandise.

Pharmaceutical Manufacturing and Sales Business:

Segment Sales / Operating Income

8,000

4,000

0

3,871

1H FY3/12


(Millions of yen)

	1H FY3/14	1H FY3/15	1H FY3/16	Difference	YoY growth rate
Net sales	11,090	13,389	15,367	1,977	14.8%
Operating income	282	836	1,210	373	44.7%
% to sales	2.6%	6.2%	7.9%	-	-
 *Before eliminations for inter-segment transactions 					
(Millions of yen) 16,000		11,090	13,389	15,36	7

1H FY3/14

1H FY3/15

1H FY3/16



5,399

1H FY3/13




Medical Professional Staffing and Placement Business:

Segment Sales / Operating Income

Page 12


P

NIHON CHOUZAI



II. Business Development of the Nihon Chouzai Group

Page 14 **ID** NIHON CHOUZAI




1. Contributing to Growth in the Use of Generic Drugs

Page 15 NIHON CHOUZAI


Generic Drug Utilization Rate by Nihon Chouzai Pharmacies (Volume basis)

As of October 2015



1. Contributing to Growth in the Use of Generic Drugs






Results of Operations First Half of FY3/16

2. Initiatives for At-home Nursing Care

Page 17



Number of Premiums and Ratio of Pharmacies Involving At-home Medical Care




Results of Operations First Half of FY3/16

(Ratio of pharmacies

3. Store Openings

Page 18

NIHON CHOUZAI



- 4. Benefits of Separating Drug Prescribing and Dispensing at Three Locations in Asahi City
 - Generic Drug Utilization Rate at Each Pharmacy (Volume basis) (October 2015)



- Open 24 hours
- Provides nighttime services



- Sterile prescription dispensing room (clean room)
- Conference and seminar room



P

Page 19

NIHON CHOUZAI

Asahi Station Front Pharmacy

• "Mentaio" (diversified customeroriented) pharmacies


Converting to generic drugs reduces drug costs

Total reduction at all three locations: ¥273 million (annual estimate)

Page 20 DIHON CHOUZAI

A Favorable Environment for Generic Drugs in Japan

Generic Drug Market Share Growth in Japan and Targets



Note: The volume-based share is the volume of generic drugs divided by the sum of the volumes of original drugs with generic versions and generic drugs. (Research by the Ministry of Health, Labour and Welfare)

Source: Website of the Ministry of Health, Labour and Welfare

The Basic Policy by the Japanese government

"The government will aim to increase the volume-based share of generic drugs to greater than 70% by mid-2017 and to greater than 80% as soon as possible between FY2018 and the end of FY2020."


> Source: Basic Policy on Economic and Fiscal Management and Reform 2015 –Without economic revitalization, there can be no fiscal consolidation–

5. Pharmaceutical Manufacturing and Sales Business

Page 21

NIHON CHOUZAI

Number of Product Items



New NHI Drug Listings for December 2015 (9 items)

Name	Name	Name	
Amvalo Combination Tablets "JG"	Olopatadine Hydrochloride OD Tablets 5mg "JG"	Ethyl Icosapentate Granular Capsules 300mg "CH"	
Losarhyd Combination Tablets HD "JG"	Sertraline Tablets 25mg "JG"	Ethyl Icosapentate Granular Capsules 600mg "CH"	
Olopatadine Hydrochloride OD Tablets 2.5mg "JG"	Sertraline Tablets 50mg "JG"	Ethyl Icosapentate Granular Capsules 900mg "CH"	

Page 22

🕑 NIHON CHOUZAI

Maximum Annual Output Capacity (tablets and capsules)

(Unit: 100 million tablets)

Company name	Plant name	FY3/14	FY3/15	Plan
	Tsukuba Plant (S, N)	10	23	36
Nihon Generic	Tsukuba Plant No. 2			100
	Kasukabe Plant		9	9
	Head Office Plant	7	7	7
Choseido Pharmaceutical	Head Office Plant No. 2		2	2
	Kawauchi Plant	2	2	2
	Total	1.9 billion tablets	4.3 billion tablets	15.6 billion tablets

Page 23 **IIHON CHOUZAI**


Completion Image of the Tsukuba Plant No. 2



6. Expansion of Medical Professional Staffing and Placement Business



Number of New Register for Placement and Total Job Offers



7. The Outlook for Pharmacies



A Vision for Pharmacies That Put Customers First


Source: Website of the Ministry of Health, Labour and Welfare

Support for staying healthy	• Contribute to preventing diseases and staying healthy for the people
Advanced pharmacology management	Meet requirements for advanced supervision of drug use
Centralize drug use data/ Continuous monitoring	 Constantly monitor benefits and check for side effects Prevent excessive/overlapping use of drugs and harmful drug interactions Use ICT to monitor prescription data for an individual from all medical institutions
24-hour service/ At-home service	 24-hour/365-day operation Drug use oversight and assistance in using drugs for people at home
Working with medical institutions	 Prescription questions for doctors/Prescription suggestions Feedback about side effects and drug use Consultations about drugs and staying healthy Recommendations for care at a medical institution

8. Business Development of the Nihon Chouzai Group

Page 26 NIHON CHOUZAI

Segment Operating Income



Dispensing pharmacy business
 Pharmaceutical manufacturing and sales business
 Medical professional staffing and placement business

* Before adjustments for segment profit

8. Business Development of the Nihon Chouzai Group

Page 27

🕑 NIHON CHOUZAI

Dispensing pharmacy business	Information provision and consulting business
NIHON CHOUZAI Co., Ltd.	Japan Medical Research Institute Co., Ltd.

NIHON CHOUZAI Group

Pharmaceutical manufacturing and sales business

Nihon Generic Co., Ltd. Choseido Pharmaceutical Co., Ltd. Medical professional staffing and placement business

Medical Resources Co., Ltd.



Precautions

This presentation was prepared for the purpose of providing additional information concerning the October 29, 2015 announcement of results of operations for the first half of the fiscal year ending on March 31, 2016 (*kessan tanshin*). Performance targets, plans, business activities and other forward-looking statements concerning Nihon Chouzai and its subsidiaries are based on information that was available when this presentation was made. There may be significant changes to these statements due to business and other risk factors and other uncertainties. In addition, these statements are not promises concerning future performance. Actual results of operations may differ significantly from the outlook in this presentation for a number of reasons. In addition, this presentation is not a solicitation to make an investment in Nihon Chouzai. Investment decisions are the responsibility of individual investors.

Inquiries:



NIHON CHOUZAI Co., Ltd.

Corporate Planning Department, Investor Relations Group 37F GranTokyo North Tower, 1-9-1, Marunouchi, Chiyoda Ward, Tokyo 100-6737, JAPAN

TEL: +81-(0) 3-6810-0800 (general) E-mail: ir-info@nicho.co.jp IR website: http://www.nicho.co.jp/ir